Catalent Inc Stock Price, News & Analysis

Catalent, Inc. (NYSE: CTLT) has released its fourth Corporate Responsibility Report for the fiscal year 2022, ending June 30, showcasing advancements in environmental, social, and governance (ESG) commitments. The company manufactured 80 billion doses across 8,000 products, supporting the launch of 150 new medicines. Catalent has reduced greenhouse gas emissions by 38% from a fiscal 2020 baseline and aims for a 42% reduction by 2030. Additionally, it has committed to zero waste to landfill by 2024, with 60% of sites achieving this milestone. The report also highlights increased diversity efforts and over $1.3 million in philanthropic contributions.

Catalent, Inc. (NYSE: CTLT) has appointed Joseph A. Ferraro as its Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary, based in Somerset, New Jersey. Mr. Ferraro brings extensive experience from his tenure at Innovate Corp. (NYSE: VATE) and Prospect Capital (NASDAQ: PSEC), where he managed global legal and compliance operations, including significant M&A transactions. He will lead Catalent's legal and compliance teams and report to Steven Fasman, Chief Administrative Officer. This strategic appointment is expected to enhance Catalent's legal oversight as it navigates the highly regulated life sciences market.

Catalent reported Q2'23 net revenue of $1.15 billion, reflecting a 6% decrease compared to Q2'22, or 2% in constant currency. Organic net revenue fell 4%. The company posted net earnings of $81 million and Adjusted EBITDA of $283 million, down 9% as reported. Catalent reiterated its full-year guidance of $4,625 million to $4,875 million in net revenue and $1,220 million to $1,300 million in Adjusted EBITDA. Additionally, Catalent and Moderna are extending their collaboration for manufacturing multiple products across North America and Europe, enhancing their ongoing partnership in both COVID and non-COVID programs.

Catalent, Inc. (NYSE: CTLT) will release its financial results for Q2 fiscal 2023, ending December 31, 2022, before the market opens on February 7, 2023. A management webcast will follow at 8:15 a.m. ET to discuss the results. Interested parties can access the webcast via Catalent’s investor website. The company, a leader in optimizing product development and supply for pharma and biotech, generated nearly $5 billion in revenue during its last fiscal year.

Catalent, Inc. (NYSE: CTLT) has appointed Ricardo Zayas as Senior Vice President of Operations for Biologics North America. Zayas will oversee North American biologics operations, including fill/finish services in Bloomington, Indiana and gene therapy manufacturing in Harmans, Maryland. Reporting to CEO Alessandro Maselli, Zayas brings over 30 years of experience in pharmaceutical manufacturing, having previously served as COO at Ocyonbio and holding leadership roles at Romark Pharmaceuticals and Bristol-Myers Squibb. This strategic appointment aims to enhance Catalent's operational excellence and support growth in innovative treatments.

Avantor has entered into a multi-year supply and services agreement with Catalent to provide a wide range of laboratory supplies, clinical materials, and services. This partnership aims to enhance both companies' capabilities in delivering better treatments to patients and reflects their commitment to meeting global health needs. The collaboration builds on an existing relationship, showcasing Avantor's strengths in reliability and innovation.

Catalent and Sarepta Therapeutics have entered into a commercial supply agreement for Catalent to manufacture Sarepta’s gene therapy candidate, delandistrogene moxeparvovec (SRP-9001), aimed at treating Duchenne muscular dystrophy (DMD). This agreement names Catalent as Sarepta's primary manufacturing partner for SRP-9001 and supports additional candidates in Sarepta’s pipeline for limb-girdle muscular dystrophy (LGMD). Catalent boasts advanced manufacturing capabilities with 10 cGMP gene therapy suites, with 8 more under construction.

Catalent, Inc. (NYSE: CTLT) will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 5:15 p.m. EST. Members of the executive leadership team will present, and a live webcast will be available at investor.catalent.com. Catalent is a leader in pharmaceutical and biotech development, generating nearly $5 billion in revenue in FY 2022. The company supports over 1,000 partner programs and launches 150 new products annually, with a workforce of approximately 18,000 professionals.

Catalent (NYSE: CTLT) has appointed J. Martin Carroll, the lead independent director, as its new Chair, effective after the retirement of John Chiminski on June 30, 2023. Chiminski led the company for over 13 years. Other board members, Rolf Classon and Peter Zippelius, are also set to retire. Carroll aims to build upon Catalent’s growth and strategic objectives, emphasizing the board's commitment to refreshment and shareholder value. The board will be reduced to 11 directors post-retirement, with a diverse composition.